Plain-English translation of NCT07592585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase III trial testing a medication called to see if it can safely and effectively treat mild to moderate atopic dermatitis (eczema) in teenagers and adults. Researchers will compare the medication to a placebo (inactive treatment) to understand how well it works. About 360 people will participate across multiple centers.
Atopic dermatitis is a chronic skin condition that causes itching, inflammation, and discomfort, and many people don't have enough treatment options that work well for them. This trial is testing whether this new treatment could provide a safe and effective option for people with mild to moderate forms of the condition.
You likely qualify if…
You likely don't qualify if…
Participants will be randomly assigned to receive either the new medication or a placebo, and neither they nor the researchers will know which group they're in (this is called double-blinded). You'll apply the treatment as directed and visit the clinic for check-ups where doctors will examine your skin and ask about any side effects. The exact length and number of visits will be determined by the study team, but you should be prepared for regular appointments over several weeks or months.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China